At moments of regional tension, attention narrows to the immediate. Markets react, risk is repriced and timelines compress. The current escalation with Iran is having a tangible impact: business activity has slowed, projects have been delayed, and critical infrastructure has come into sharper focus. But the most consequential economic shifts are not shaped by the news cycle alone. They are built over decades.
Across the Gulf, that long-term orientation is becoming increasingly visible in two sectors that will define the next phase of global growth: artificial intelligence and life sciences. Even as near-term uncertainty rises, investment in both continues. These are not discretionary bets that can simply be paused. They are long-cycle, capital-intensive systems. Delays are possible. Abandonment is not.
The next phase of AI won’t be determined by applications alone, but by access to compute, energy, data and talent – foundational requirements that only a handful of places can realistically assemble at scale. The Gulf is positioning itself as one of them.
In the United Arab Emirates, G42 has become a central player in AI infrastructure and applied systems, with capabilities spanning healthcare, energy and sovereign cloud. Its partnership with Microsoft – a $1.5 billion investment backed by a first-of-its-kind intergovernmental assurance agreement between the US and UAE – reflects a broader shift: global tech firms are increasingly viewing the region not simply as a market, but as a strategic base for deployment. That the deal required binding commitments on technology transfer, cybersecurity and responsible AI is itself revealing. This is not peripheral activity. It is consequential enough to demand the attention of governments.
Saudi Arabia is pursuing a similarly ambitious path. The clearest expression of that ambition is Humain, a PIF-owned company launched in 2025 and chaired by Crown Prince Mohammed bin Salman, whose stated goal is to build the entire AI stack – data centres, cloud infrastructure, models and applications – under a single sovereign entity. Humain has announced $23 billion for strategic technology partnerships CNBC and secured deals with Nvidia, AMD and Groq, with construction under way on large-scale data centre campuses across the Kingdom. The intent is explicit: to become the third-largest AI provider in the world, behind the United States and China.
Taken together, these efforts point to a structural shift. The Gulf is no longer passively adopting technologies developed elsewhere. It is participating in the shape, design and deployment of the systems that underpin them.
A similar pattern is emerging in life sciences. For much of the past decade, biotechnology innovation has been concentrated in a small number of hubs in the United States and Europe. As the cost and complexity of biomedical innovation increase, new sources of capital and new geographies are becoming more relevant.
Across the region, Mubadala and ADQ in Abu Dhabi, Saudi Arabia’s domestic biotech push and Qatar’s continued support for biomedical research institutions are collectively expanding the Gulf’s presence across research, manufacturing and clinical development. International companies are responding: partnerships in clinical trials, genomics and data-driven medicine are becoming more common, drawn by capital depth and access to diverse datasets.
What links these developments isn’t simply sectoral focus, but a shared investment logic. Both AI and life sciences require patience. Breakthroughs are uncertain, timelines are long and returns are often non-linear. In many Western markets, where capital is increasingly judged on short-term performance, this creates friction. In the Gulf, where investors can operate with longer horizons, it creates opportunity.
Geopolitical risk in this region is not a distant variable. It is ambient. Those closest to it understand better than most that uncertainty is not a reason to pause – it is the condition under which serious long-term building has always happened.
That mindset is visible in how the Gulf continues to invest in AI and life sciences even as tensions in the neighbourhood rise. The infrastructure being laid – in compute, in clinical research, in sovereign data systems – is not contingent on a stable external environment. It is, in part, a hedge against one.
In artificial intelligence and life sciences, success won’t be defined by the fastest mover in any given quarter, but by who builds most consistently over time. Consistency is itself a strategic asset. By that measure, the Gulf’s long game is already underway.
